Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | PGR | P06401 | 2/20 | 0.77 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | SHBG | P04278 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | AR | P10275 | 1/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12045184 | 1.00 | HIF1A (0.81) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL13044945 | 1.00 | HIF1A (0.81) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL1685788 | 1.00 | HIF1A (0.81) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL22872809 | 1.00 | HIF1A (0.81) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL21231472 | 0.92 | HIF1A (0.78) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL21340506 | 0.90 | HIF1A (0.75) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL1685722 | 0.90 | HIF1A (0.77) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL25854534 | 0.90 | HIF1A (0.77) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL1685723 | 0.90 | HIF1A (0.77) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL14523057 | 0.90 | HIF1A (1.00) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190224164-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF COPD | BODOR LABORATORIES, INC. | 2019-07-25 | — | — | US | claimed |
| US-20120177590-A1 | SOFT ANTICHOLINERGIC ESTERS | BODOR LABORATORIES, INC. | 2012-07-12 | — | — | US | claimed |
| US-20120141401-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | BODOR LABORATORIES, INC. | 2012-06-07 | — | — | US | claimed |
| EP-1948596-B1 | SOFT ANTICHOLINERGIC ESTERS | BODOR NICHOLAS S (US) | 2011-10-19 | — | — | EP | claimed |
| EP-1957451-B1 | SOFT ANTICHOLINERGIC ZWITTERIONS | BODOR NICHOLAS S (US) | 2011-10-19 | — | — | EP | claimed |
| US-7923441-B2 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2011-04-12 | — | — | US | claimed |
| US-7776846-B2 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2010-08-17 | — | — | US | claimed |
| EP-1653974-B1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR NICHOLAS S (US) | 2010-01-06 | — | — | EP | claimed |
| US-20090263341-A1 | SOFT ANTICHOLINERGIC ESTERS | BODOR LABORATORIES, INC. | 2009-10-22 | — | — | US | claimed |
| US-20090257969-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | BODOR LABORATORIES, INC. | 2009-10-15 | — | — | US | claimed |
| US-20090075954-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | BODOR LABORATORIES, INC. | 2009-03-19 | — | — | US | claimed |
| US-20080261930-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR LABORATORIES, INC. | 2008-10-23 | — | — | US | claimed |
| US-20080242651-A1 | 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-10-02 | — | — | US | claimed |
| US-7419971-B2 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2008-09-02 | — | — | US | claimed |
| US-7417147-B2 | muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-08-26 | — | — | US | claimed |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-01-31 | — | — | US | claimed |
| EP-1658083-B1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS | BODOR NICHOLAS S (US) | 2007-08-08 | — | — | EP | claimed |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2007-05-31 | — | — | US | claimed |
| US-20050026892-A1 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2005-02-03 | — | — | US | claimed |
| US-20050020551-A1 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2005-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263341-A1 | SOFT ANTICHOLINERGIC ESTERS | CHRM2, CHRM1, CHRM3 | HIF1A 4585/4885LMNA 1719/4885NR3C1 1356/4885 |
| US-20120177590-A1 | SOFT ANTICHOLINERGIC ESTERS | CHRM2, CHRM1, CHRM3 | HIF1A 4585/4885LMNA 1719/4885NR3C1 1356/4885 |
| US-20050020551-A1 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | NR3C1, NR3C2, HSD17B7 | HIF1A 1389/4885LMNA 3415/4885NR3C1 1/4885 |
| US-20080261930-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | NR3C1, NR3C2, HSD17B7 | HIF1A 1389/4885LMNA 3415/4885NR3C1 1/4885 |
| US-20120141401-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | CHRM2, CHRM1, CHRM3 | HIF1A 4791/4885LMNA 2819/4885NR3C1 1856/4885 |
| US-20090257969-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | CHRM2, CHRM1, CHRM3 | HIF1A 4791/4885LMNA 2819/4885NR3C1 1856/4885 |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | CHRM2, ADRB2, ADRB1 | HIF1A 3363/4885LMNA 3838/4885NR3C1 16/4885 |
| US-20080242651-A1 | 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | CHRM2, CHRM1, CHRM3 | HIF1A 3390/4885LMNA 4285/4885NR3C1 19/4885 |
| US-20190224164-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF COPD | CHRM3, CHRNG, CHRM2 | HIF1A 634/4885LMNA 3231/4885NR3C1 115/4885 |
| US-20090075954-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | CHRNE, CHRM1, ADRB1 | HIF1A 1841/4885LMNA 3526/4885NR3C1 205/4885 |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | CHRM2, ADRB1, ADRB2 | HIF1A 3671/4885LMNA 3178/4885NR3C1 588/4885 |
| US-20050026892-A1 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | OXER1, ELOVL6, ELOVL3 | HIF1A 1572/4885LMNA 1749/4885NR3C1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.